Cargando…
帕博利珠单抗联合安罗替尼四线治疗EGFR基因敏感突变阳性肺腺癌1例
45.7% of Chinese patients with advanced lung adenocarcinoma were reported to harbour sensitizing epidermal growth factor receptor (EGFR) mutations. Limited therapeutic options are left for non-small cell lung cancer (NSCLC) harbouring sensitizing EGFR mutations after failure of EGFR-tyrosine kinase...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560986/ https://www.ncbi.nlm.nih.gov/pubmed/34628779 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.25 |
_version_ | 1784593038770700288 |
---|---|
collection | PubMed |
description | 45.7% of Chinese patients with advanced lung adenocarcinoma were reported to harbour sensitizing epidermal growth factor receptor (EGFR) mutations. Limited therapeutic options are left for non-small cell lung cancer (NSCLC) harbouring sensitizing EGFR mutations after failure of EGFR-tyrosine kinase inhibitor (TKI) therapy and chemotherapy, finding effective options for them is an unmet clinic need. Herein we reported a case that till January 12, 2021, an 82-year-old female with sensitizing EGFR-mutant advanced lung adenocarcinoma received a surprising progression-free survival (PFS) benefit of over 21 months from the combination therapy of pembrolizumab and anlotinib after her failure of treatments of osimertinib, chemotherapy and anlotinib-monotherapy. |
format | Online Article Text |
id | pubmed-8560986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-85609862021-11-10 帕博利珠单抗联合安罗替尼四线治疗EGFR基因敏感突变阳性肺腺癌1例 Zhongguo Fei Ai Za Zhi 病例报道 45.7% of Chinese patients with advanced lung adenocarcinoma were reported to harbour sensitizing epidermal growth factor receptor (EGFR) mutations. Limited therapeutic options are left for non-small cell lung cancer (NSCLC) harbouring sensitizing EGFR mutations after failure of EGFR-tyrosine kinase inhibitor (TKI) therapy and chemotherapy, finding effective options for them is an unmet clinic need. Herein we reported a case that till January 12, 2021, an 82-year-old female with sensitizing EGFR-mutant advanced lung adenocarcinoma received a surprising progression-free survival (PFS) benefit of over 21 months from the combination therapy of pembrolizumab and anlotinib after her failure of treatments of osimertinib, chemotherapy and anlotinib-monotherapy. 中国肺癌杂志编辑部 2021-10-20 /pmc/articles/PMC8560986/ /pubmed/34628779 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.25 Text en 版权所有©《中国肺癌杂志》编辑部2021 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/. |
spellingShingle | 病例报道 帕博利珠单抗联合安罗替尼四线治疗EGFR基因敏感突变阳性肺腺癌1例 |
title | 帕博利珠单抗联合安罗替尼四线治疗EGFR基因敏感突变阳性肺腺癌1例 |
title_full | 帕博利珠单抗联合安罗替尼四线治疗EGFR基因敏感突变阳性肺腺癌1例 |
title_fullStr | 帕博利珠单抗联合安罗替尼四线治疗EGFR基因敏感突变阳性肺腺癌1例 |
title_full_unstemmed | 帕博利珠单抗联合安罗替尼四线治疗EGFR基因敏感突变阳性肺腺癌1例 |
title_short | 帕博利珠单抗联合安罗替尼四线治疗EGFR基因敏感突变阳性肺腺癌1例 |
title_sort | 帕博利珠单抗联合安罗替尼四线治疗egfr基因敏感突变阳性肺腺癌1例 |
topic | 病例报道 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560986/ https://www.ncbi.nlm.nih.gov/pubmed/34628779 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.25 |
work_keys_str_mv | AT pàbólìzhūdānkàngliánhéānluōtìnísìxiànzhìliáoegfrjīyīnmǐngǎntūbiànyángxìngfèixiànái1lì AT pàbólìzhūdānkàngliánhéānluōtìnísìxiànzhìliáoegfrjīyīnmǐngǎntūbiànyángxìngfèixiànái1lì AT pàbólìzhūdānkàngliánhéānluōtìnísìxiànzhìliáoegfrjīyīnmǐngǎntūbiànyángxìngfèixiànái1lì AT pàbólìzhūdānkàngliánhéānluōtìnísìxiànzhìliáoegfrjīyīnmǐngǎntūbiànyángxìngfèixiànái1lì AT pàbólìzhūdānkàngliánhéānluōtìnísìxiànzhìliáoegfrjīyīnmǐngǎntūbiànyángxìngfèixiànái1lì |